Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro^TM, Supor^TM, iCELLis^TM, and Kleenpak^TM, in addition to ÄKTA^TM, Amersham^TM, Biacore^TM, FlexFactory^TM, HyClone^TM, MabSelect^TM, Sefia^TM, Whatman^TM, and Xcellerex^TM. Visit cytiva.com for more.
关于Cytiva（思拓凡）
Cytiva（思拓凡） 和 Pall（颇尔）生命科学业务合并，携手共同为研究人员和生物制药企业提供广泛多元的产品组合和专业的技术支持与服务，推动创新疗法从研发到商业化的发展。全新的Cytiva全面助力客户提升工作质量、速度与安全性，赋能创新型药物的开发和生产，惠及全球患者。合并后，Cytiva的产品品牌包括Allegro^TM，Supor^TM，iCELLis^TM 和 Kleenpak^TM，以及ÄKTA^TM，Amersham^TM，Biacore^TM，FlexFactory^TM，HyClone^TM，MabSelect^TM，Sefia^TM，Whatman^TM 和 Xcellerex^TM。
更多信息，敬请访问cytiva.com.cn
智荟专线：400-810-9118
官微订阅号：Cytiva

Sony Biotechnology Inc. is dedicated to helping researchers working across different life science disciplines to achieve the best scientific results. By leveraging Sony's vast know-how in electronics innovation and design we offer next-generation cell analysis and sorter systems to accelerate your discoveries. Our goal is to bring a unique perspective to the flow cytometry tools required for in-depth single cell isolation and analysis. With our core expertise in automation and software development we hope to enable discovery research across immunology, oncology, cell biology and translational medicine.

Eppendorf 是一家领先的生命科学公司，在全世界开发、生产和供应用于实验室的设备和解决方案。业务范围分为液体处理、耗材、分离与仪器、生物工艺解决方案，产品线包括移液器、吸头、离心机、混匀仪和超低温冰箱等等。此外，Eppendorf 还提供使用广泛的高品质耗材。 Eppendorf 的产品广泛应用于科研和商业性研发实验室，例如制药和生物技术、化学以及食品等行业。此外，我们的产品也被临床和环境分析实验室、法医和工业类用户在工艺分析、生产和质量检测等环节广泛使用。 Eppendorf 成立于 1945 年，总部位于德国汉堡，并在世界各地拥有约 5,000 名员工。集团在 33 个国家设有子公司，并在所有大洲和重要市场设有分销商。

上海唯可生物科技有限公司，由德国海德堡大学病毒整合位点评估方法的金标准LAM-PCR的发明团队成立，长期专注于病毒整合位点分析（ISA），在基因治疗安全评价领域拥有20多年技术积累，为全球90%以上基因治疗产品提供了满足CDE、FDA、EMA监管要求的插入突变相关的安全性解决方案，助力产品成功上市、并提供持续的长期随访服务。 主要业务有：载体安全性评估（使用S-EPTS/LM-PCR、Multiplex LAM-PCR方法进行整合位点检测及安全性评估分析、载体拷贝数检测）、基因编辑安全性评估（On-/Off- target、Translocation、iGUIDE-seq、TES、PEM-seq等）、AAV质控分析、细胞库单克隆鉴定、分析方法开发与方法学验证等。

美迪西（股票代码：688202.SH）成立于2004年，总部位于上海，是一家专业临床前综合研发服务CRO，为全球的医药企业和科研机构提供符合国内及国际申报标准的一站式新药研发服务。公司服务涵盖医药临床前新药研究的全过程，主要包括药物发现、药学研究及临床前研究。药物发现研发服务项目包括蛋白靶标验证、结构生物学、化学合成、化合物活性筛选及优化等；药学研究包括原料药与制剂工艺研究、质量标准和稳定性研究等；临床前研究包括药效学、药代动力学、毒理学安全性评价研究等。至2024年6月底，美迪西已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有490件IND获批临床。

作为一家专注于AAV 技术十年，深耕基因治疗领域的CRO & CTDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。截至2024年，派真已经服务了全球 30 多个国家，50 多个 MNC， 成功交付10000+AAV定制包装服务，累计超过200批中试生产经验，已成功协助合作伙伴以零发补获得十多个FDA和NMPA IND批件,成功交付数十个IIT项目。派真生物以“让老百姓用得起基因治疗”为使命，以加速创新基因药上市为己任，笃行成为最高效的基因治疗服务平台，助力合作伙伴让基因药更早普惠大众。
Packgene Biotech is a world-leading CRO and CTDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development,and cell and gene therapy trials, we deliver cost-effective,dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
PackGene offers 8,000m² state-of-the-art GMP facilities in compliance with the FDA, NMPA, and EMA regulatory requirements with the first 4,000L GMP AAV production capacity in Asia. We have successfully delivered over 10,000 batches of research-grade AAV packaging services for hundreds of big pharma, biotech and research institutions from the United States, Europe, Asia Pacific, and China. We dedicate ourselves to the new serotype AAV vectors development and high-yield AAV production technology to accelerate your gene therapy programs. PackGene continuously strives to improve the quality, yield, efficacy, and safety of plasmid DNA and AAV vector to make gene therapy affordable for patients.

楷拓生物是一家聚焦生物医药新技术开发和应用的创新科技公司，矢志为全球基因细胞治疗药物与核酸药物提供从药物研发、质量研究、临床应用到产业化的全产业链一站式CRDMO服务。公司在中国、美国和瑞士等地设有运营基地，在苏州、武汉设有研发中心和GMP产业化基地。楷拓生物核心团队均来自于国际和国内顶尖生物科技公司与国内外知名院校和科研机构，在基因治疗与核酸治疗领域拥有丰富的产业技术与管理经验。公司以高质量大规模质粒工艺开发与生产、mRNA合成及递送全流程工艺开发与生产、核酸分析方法与质量研究四大核心技术服务平台为起点，立志打造顶尖工艺技术平台，成为新一代创新生物科技行业之楷范。

珠海舒桐医疗科技有限公司是一家以基因编辑为核心技术的生物医药企业，总部位于粤澳深度合作区——横琴新区，下设鼓润（武汉）医疗科技有限公司、广州舒桐医疗科技有限公司和杭州舒桐生物科技有限公司等全资子公司。公司为国家高新技术企业，拥有博士后工作站和多个博士后团队，已申请专利40余项，承担多项国家科技重大专项。公司致力于通过创新技术为多种疾病尤其肿瘤开展新药研发，提供基因靶向治疗方案。同时公司搭建了一站式基因编辑平台、分子诊断平台和科技服务平台，可提供从靶点筛选、基因编辑有效性检测到安全性评估的全流程解决方案；具备先进的CGT原料规模化生产能力，可为科研机构及生物医药企业提供安全高效的一站式服务和原料供应。舒桐医疗坚持以“创新、敬业、融合、开放”为核心价值观，致力于利用基因治疗技术造福人类健康，让生命更美好。

江苏东抗生物医药科技有限公司由资深生物制药背景团队在2016年创立，是一家致力为全球提供高品质重组蛋白原料的国家高新技术企业。公司主要产品有细胞培养蛋白原料和IVD诊断蛋白原料。其中细胞培养蛋白原料包括了各种GMP级别的细胞因子、生长因子，转铁蛋白、纤连蛋白和CD系列抗体等重组蛋白，并且有10多款产品已经完成DMF备案。公司过往投入近2亿元在南通和苏州建设了一流的重组蛋白研发、验证与生产技术平台，拥有10000+平米场地、110+人组成的专业团队和CHO细胞株全球商业化授权。公司目前为江苏省专精特新企业，与双一流高校共建蛋白研究联合实验室。东抗生物未来将践行“改善生命健康”的使命，助力细胞治疗产业发展。

厦门福流生物科技有限公司（NanoFCM）自主研发的纳米流式检测仪（Flow NanoAnalyzer）可对单个纳米颗粒（7-1000 nm）的粒径及其分布、颗粒浓度以及生物化学性质进行高分辨、高选择性、高通量检测，是目前市面上真正具有单个纳米颗粒（<100 nm）多参数综合表征的流式产品，填补了国际空白。NanoFCM在外泌体、疫苗、病毒、核酸药物等生物医药领域均有成熟的解决方案，客户遍布全球顶级研究机构和生物医药巨头，在国际上享有盛誉，对所在领域起到标杆性作用，如Mayo Clinic、MD Anderson Cancer Center、NIH、牛津大学、帝国理工学院、Codiak Biosciences、EVOX、LONZA、Novo Nordisk、百时美施贵宝等均为我们的客户。

为度生物以“成就生命健康”为使命，不断开拓创新，引领生物医疗科技产业的发展。从细胞到外泌体、从细胞分选到流式分析、从科研到转化医学甚至临床诊断、从试剂耗材到仪器设备，为度生物为前沿生命科学提供多维度的解决方案！产品涉及流式抗体、抗体原料、诊断试剂、细胞分选磁珠、各类微球原料、外泌体检测/定量等试剂，以及流式分析仪、磁性细胞分选仪、纳米流式仪等，服务于创新医药的研发、质控、生产等各个环节。

武汉宏韧生物医药股份有限公司成立于 2011 年，总部位于武汉市东湖高新区，武汉、上海和广州三地的实验和办公场所面积超过18000m2，是一家以临床生物分析和非临床药代动力学研究为特色的药物研发技术服务CRO企业，主要业务包括临床生物分析、非临床药代动力学和药效学研究、数据管理与统计分析等领域。
专业团队超过 480人，配备分析检测相关仪器超过200台。目前已完成1200多个化学仿制药BE生物分析检测项目、500多个非临床药代动力学项目和300多个创新药物的临床生物分析项目，品种涵盖各类化学药物、中药和生物制品。目前，宏韧医药参与生物分析检测的项目中已有400多个获得国家药监局颁发的生产批件或新药证书。
Wuhan Hongren Biopharmaceutical Co., Ltd. was established in 2011 and is headquartered in East Lake Hi-Tech Zone, Wuhan. The laboratory and office space in Wuhan, Shanghai and Guangzhou covers an area of more than 18,000m2. It is a drug research and development technology service CRO company specializing in clinical bioanalysis and non-clinical pharmacokinetic research. Its main businesses include clinical bioanalysis, non-clinical pharmacokinetics and pharmacodynamics research, data management and statistical analysis.
The professional team has more than 480 people and is equipped with more than 200 analytical and testing instruments. At present, it has completed more than 1,200 BE bioanalysis and testing projects for chemical generic drugs, more than 500 non-clinical pharmacokinetic projects, and more than 300 clinical bioanalysis projects for innovative drugs, covering various types of chemical drugs, traditional Chinese medicines, and biological products. At present, more than 400 of the bioanalysis and testing projects in which Hongren Pharmaceuticals has participated have obtained production approvals or new drug certificates issued by the State Food and Drug Administration.

ATLATL飞镖创新中心是全球化的生命科学研发创新平台，在北京、上海、深圳、新加坡、香港等地均设有研发中心。
ATLATL为客户提供覆盖药物活性检测、动物疾病模型构建和药效评估等各阶段的综合研发服务，支持大分子、小分子、核酸药物、基因与细胞治疗、药物递送等关键方向，以及多组学分析、基因编辑、类器官和器官芯片等前沿领域，并为科研人员打造卓越的实验环境和精细化的运营管理。
通过与全球领先企业和研究机构的深入合作，ATLATL在研发资源整合与能力共享上不断创新，以先进的系统化研发模式加速生命科学的工程化进程，使科研成果得以迅速、高效地转化为临床实践，助力全球生命科学创新，造福人类健康。

谱新生物，定位于拥有产业化核心技术的细胞与基因治疗药物CDMO企业。公司整体由细胞治疗领军企业-深圳普瑞金生物药业有限公司的CDMO业务分拆后独立运营。公司股东包括国家中小企业发展基金、中科院控股国科嘉和基金、海尔医疗、华邦健康、湖南健康养老基金等，公司总部位于美丽的太湖之滨-苏州市吴中区，注册资本1亿元。公司拥有苏州总部（7000m2 GMP厂房）、郑州基地（7000m2 GMP厂房在建），初步形成全国布局的生产基地网络布局。 江苏谱新聚焦于细胞与基因治疗药物领域，搭建了核酸类产品工艺开发平台、悬浮无血清病毒培养平台和全封闭的细胞工艺开发平台，打造了从药物发现到产品交付的高速公路。平台已支持多个合作伙伴成功孵化了多款CAR-T、TCR-T、干细胞、mRNA等药物，致力于让更多项目更早更快地达到下一里程碑，把更多细胞与基因治疗药物推向市场，造福更多患者，谱写细胞与基因治疗中国新。

作为血液成分、治疗性单采与细胞技术领域的全球综合方案提供商，泰尔茂比司特（Terumo Blood and Cell Technologies） 是一家具有单采血液成分、手工与自动化全血加工、自动化细胞扩增及细胞处理方面独特产品组合的企业。我们坚信, 血液和细胞的潜能会远远超出当前对患者所起的作用, 这种信念激发了我们的创新能力, 加强我们与客户的合作。
Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, cell expansion and processing technologies. we believe in the potential of blood and cell to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

楚天科技股份有限公司创立于2000年，现已成为世界医药装备行业的主要企业之一。主营业务系医药装备及其整体技术解决方案，并率先推动智慧医药工厂的研究与开发。全球员工总数7000多人，2021年营业收入52.6亿元，工业产值超60亿元，总资产近100亿元。2022年营业收入64.5亿元（未经审计），工业产值超70亿元。中国医药装备行业排名第一（以营业收入统计）。公司系中国A股上市公司，旗下拥有德国ROMACO集团、楚天思为康基因科技等多家全资或控股子公司，是集“生物医药装备、中药装备”等战略性新兴产业的研究、设计、销售、制造、服务于一体的进口替代型医药装备及整体解决方案提供商，并率先推动智慧医药工厂的研究与开发，是国家技术创新示范企业、国家智能制造系统解决方案供应商、国家企事业知识产权试点单位、国家职业技能等级认定试点企业、国家制造业单项冠军产品示范企业。公司先后有20项重点新产品填补了世界或国内的空白。
楚天思为康基因科技(长沙)有限公司（楚天科技控股子公司），成立于2022年2月，拥有一批生物、机械、自控、光学和视觉算法等综合交叉学科的硕博人才，核心成员在制药装备领域具有多年研究经验，同时，依托首席科学家胡璧梁博士在免疫治疗科学领域的多年深耕，以及团队在细胞药物制备领域工艺及技术的沉淀，打造高效智能的细胞药物制备解决方案。

英文：https://voisinconsulting.com
中文：https://voisinconsulting.cn
Voisin Consulting Life Sciences (VCLS) is an international clinical research and regulatory science consulting company dedicated to assisting clients in accelerating the introduction of innovative drugs and medical products to the market and benefiting patients. VCLS provides comprehensive services and customized solutions for products aiming for overseas markets, including regulatory strategy & submission, market access strategy analysis, nonclinical and clinical research planning, as well as clinical trial operation management.
Voisin Consulting Life Sciences (VCLS)是一家国际临床研究和药政咨询公司，致力于协助客户将创新的药物和医疗产品加速推向市场和惠及患者。VCLS为本地产品进入海外市场提供全方位的服务和定制化的解决方案，包括药政咨询，注册申报，市场准入策略分析，药学、非临床研究和临床研究规划，以及临床试验运营管理等。
更多信息，敬请访问我司官网https://voisinconsulting.cn，或致电13122976875详询我司专家
微信公众号：VCLS

PPC佳生集团（PPC Group）成立于1997年，是一家专注于提供药物临床研究一站式专业服务的合同研究组织（CRO），服务范围包括注册咨询、医学事务、临床监查、项目管理、数据管理、统计分析及药物安全警戒。PPC佳生集团总部位于中国上海，在中国大陆、台湾地区、韩国和日本提供全面的临床研究和实验室服务。PPC佳生集团旗下拥有1个Ⅰ期临床研究中心，4个生物分析实验室和1个中心实验室。Novotech成立于1996年，是亚太地区最大的合同研究组织（CRO）。Novotech的服务范围覆盖澳大利亚、新西兰和亚洲各地，其服务质量得到了客户和业内的认可。 2020年10月，两家亚洲领先的合同研究组织（CRO）――Novotech与PPC佳生集团(以下简称“PPC佳生”)合并成立了Novotech Health Holdings（诺威健康），旨在打造一个充分契合并具有多地域覆盖规模性的合同研究组织（CRO）平台，以满足亚洲地区快速增长的优质临床试验服务的需求。合并后的Novotech Health Holdings（诺威健康）将成为亚洲最大的生物技术专业CRO平台，可提供从首次人体到IV期临床研究的全面临床服务。Novotech Health Holdings（诺威健康）目前拥有超过2245人的国际化专业团队，在14个国家和地区拥有21个办公地点。
PPC was established in 1997 and is a subsidiary of Novotech Health Holdings ("Novotech"). Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech Health Holdings is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of December 31, 2021, NHH had a total of 2,245 FTEs working across our offices in 14 geographies in Asia-Pacific and the United States.

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Almost 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 2,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.
As a trusted tool provider for clinicians and industry, from large to small, CliniMACS® Systems provide technologies and instruments to the clinic. From immuno-oncology, regenerative medicine, to graft engineering, you’ll find comprehensive solutions for numerous clinical settings.
Using CliniMACS Systems, cell products have been manufactured for all stages of clinical development - from discovery to IND submission and ongoing clinical trials. We are committed to supporting investigators with solutions that enable the clinical translation and practice of novel cell and gene therapies. This support includes products and services that extend the value beyond the device and consumables.

颇尔集团（Pall Corporation）为丹纳赫集团（纽约证券交易所代码：DHR）生命科学平台旗下运营公司。颇尔全球员工团结致力于解决客户在过滤、分离和纯化方面的挑战，并促进健康、安全与环保科技的进步。颇尔提供丰富的技术和解决方案，用于保障健康、保护关键运营资产、提高产品质量以及减少排放和浪费。颇尔的生命科学和工业团队专精于服务各类行业的众多客户，包括生物技术、制药、医疗、食品饮料、实验室、微电子、航空航天、燃油石化、化工、汽车和电力等。
颇尔（中国）有限公司是颇尔集团在华独资企业，在中国历经二十多年的发展，已经由一个专注于过滤产品的公司发展为过滤、分离和纯化解决方案的专家。从上游研发到规模生产，从售前技术支持到售后服务，从产品销售到提供整体解决方案，颇尔不仅提供给客户高科技的产品和应用，更扮演着权威技术及创新品质的先锋角色。
Pall Corporation is an operating company within Danaher’s (NYSE: DHR) Life Sciences Platform. Pall associates around the world are unified by a singular drive: to solve our customers’ biggest filtration, separation and purification challenges. And, in doing so, advance health, safety and environmentally responsible technologies. Our industry-leading technologies and solutions are at work in countless applications, safeguarding health, protecting critical operating assets, improving product quality, and minimizing emissions and waste. Our Life Sciences and Industrial teams bring focused expertise to a diverse range of customers across multiple industries, including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation.
Pall (China) Co., Ltd., a subsidiary of Pall Corporation, has evolved from a specialized supplier of filtration products to the market leader of filtration, separation and purification solutions that serves a wide range of applications and industries after over 20 years of development in China. From R&D to manufacturing, from technical support to after-market services, from products to total solutions, Pall not only offers cutting-edge products and applications but also plays a pioneer role in leading technology, innovation and quality.

赛多利斯是国际领先的生命科学研究和生物制药行业合作伙伴。集团的实验室产品及服务板块为生物制药企业以及各类科研机构提供创新的实验室设备及产品，以满足客户开展高端科研实验和严苛的质控需求。集团的生物工艺解决方案板块提供全套的生物制药设备，并专注于一次性解决方案，帮助客户安全高效地生产生物药品和疫苗。集团营业额保持着两位数的年均增长率，并通过收购互补性技术不断扩大我们的业务范围。2020财年，集团销售额达23.4亿欧元。截止2020年，集团拥有约11,000名员工，60多个生产和销售基地，服务于全球用户。

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.
Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them.
Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com
About Thermo Fisher Scientific China
Thermo Fisher Scientific (China) Co., Ltd has been operating in China for over 35 years. Headquartered in Shanghai, Thermo Fisher Scientific China has branch offices in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xi’an, Nanjing, Wuhan, Jinan, and Dongguan with around 5,000 employees. Our products mainly include analytical instruments, laboratory equipment, chemical reagents, consumables, software and more; providing comprehensive laboratory solutions and serving customers across various industries.
In order to meet the local needs in China, we have established 8 manufacturing sites in Shanghai, Beijing, Suzhou and Guangzhou respectively. We also have 6 application centers and demo labs across the country which bring world-class technology and products with application development and training services to local customers. Lastly, we have the China Innovation Center in Shanghai and Suzhou, with over 100 scientists & engineers and more than 100 patents. China Innovation Center focuses on research and development supporting key vertical markets and develops products according to local demands with global advanced technologies. We have a nationwide maintenance network and China service training team, including over 2,800 professionals directly providing services for customers.
We are committed to enabling our customers to make the world healthier, cleaner and safer. For more information, please visit www.thermofisher.com.
赛默飞世尔科技简介
赛默飞世尔科技是科学服务领域的世界领导者。公司年销售额超过300亿美元。
我们的使命是帮助客户使世界更健康、更清洁、更安全。我们帮助客户加速生命科学领域的研究、解决在分析领域所遇到的复杂问题与挑战、促进医疗诊断和治疗的发展、提高实验室生产力。
我们全球超过80,000名赛默飞员工将借助于一系列行业领先的品牌Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services和Patheon，为客户提供领先的创新技术、便捷采购方案和全方位服务。欲了解更多信息，请浏览公司网站：www.thermofisher.com
赛默飞世尔科技中国简介
赛默飞世尔科技进入中国发展已超过35年，在中国的总部设于上海，并在北京、广州、香港、成都、沈阳、西安、南京、武汉、济南、东莞等地设立了分公司，员工人数约为5000名。我们的产品主要包括分析仪器、实验室设备、试剂、耗材和软件等，提供实验室综合解决方案，为各行各业的客户服务。
为了满足中国市场的需求，现有8家工厂分别在上海、北京、苏州和广州等地运营。我们在全国还设立了6个应用开发中心以及示范实验室，将世界级的前沿技术和产品带给中国客户，并提供应用开发与培训等多项服务；位于上海和苏州的中国创新中心，拥有100多位专业研究人员和工程师及100多项专利。创新中心专注于垂直市场的产品研究和开发，结合中国市场的需求和国内外先进技术，研发适合中国用户的技术和产品；我们拥有遍布全国的维修服务网点和特别成立的中国技术培训团队，在全国有超过2800名专业人员直接为客户提供服务。
我们致力于帮助客户使世界更健康、更清洁、更安全。欲了解更多信息，请登录网站：www.thermofisher.com

ArcticZymes Technologies ASA is born from the unique conditions in the Arctic and our labs in Tromsø (Norway) where we have been developing and producing cold-adapted enzymes for more than 30 years. We are specialized manufacturer of novel and high-quality recombinant enzymes for use in molecular research, in vitro diagnostics, and therapeutics. Our high-quality enzymes are an integral part of molecular research and diagnostics, either as stand-alone enzymes or as components of kits. In therapeutics such as gene therapy and vaccine production our enzymes aide the optimization of manufacturing processes. All of our products are manufactured according to ISO13485 standards and meet all REACH requirements. The unique features of our premium enzymes are accompanied by our dedication to quality, and a no-compromises approach to collaborate with our clients and partners. ArcticZymes Technologies is trusted by leading molecular research kit manufacturers, diagnostic assay developers, contract manufacturers, and therapeutic companies around the world. We provide solutions adapted to your needs. To find out more, please visit: www.arctizymes.com

上海倍笃生物科技有限公司（以下简称“倍笃生物”），成立于2018年1月，致力于为治疗领域如细胞&基因治疗、病毒载体疫苗等，诊断领域如病原微生物检测，及类器官开发等客户提供合规、高质量物料及专业服务，以期与客户共同协作，加快研发及生产进度，为客户提供更多价值。公司代理多个品牌的试剂原料，拥有完善的质量管理体系、符合监管要求的生产标准，如cGMP规范，ISO9001、ISO13485、DMF等文件，最重要的是得到行业客户广泛的认可及使用。 作为挪威ArcticZymes Technologies的战略合作伙伴，倍笃生物负责ArcticZymes Technologies产品在中国大陆的市场宣传、技术推广及商务工作，协助厂家为CGT等行业的发展做出更多的贡献。

深圳市西尔曼科技有限公司是一家专业从事生化代谢产物快速检测的研发和生产的高科技企业，是集生化分析仪器、生物传感器研发生产、快速检测方法开发、实验室仪器销售和技术服务为一体的专业厂家。由一批长期从事于实验室分析仪器应用及技术服务的专业技术人员组建，公司长期致力于为中国的生物制药、生物制品、生物技术、食品科学、生物工程、农产品加工等行业的用户提供全球先进的仪器设备，检测技术和质量管理理念。立志为中国的生物制药、食品企业的研发和生产过程提供高性价比、高精密分析仪器和方法，降低企业日常运营成本。
在全面引进母公司的技术和设计基础上，进口主要核心部件，结合深圳的制造和人才优势在大陆进行组装和调试，进一步控制成本，提供高性价比产品。仪器技术性能居于国内领先地位，部分产品已经达到国际先进水平，完全可替代进口同类产品。为满足细胞培养和发酵对产品达到更高效、更高产能、更好的产品质量的要求，推出M-online在线生化分析仪，能够近乎实时的监测生物培养过程中的葡萄糖、乳酸、谷氨酰胺、谷氨酸、铵离子、钠离子、钾离子、钙离子（赖氨酸、乙醇、甲醇、木糖、蔗糖、半乳糖、甘油、胆碱、丙酮酸）、二氧化碳（PCO2）、溶氧(PO2)、pH等主要营养成分，为您的工艺优化、生产过程提供坚实的数据溯源。现已成功推广并应用于单抗、疫苗、氨基酸、维生素、酶制剂、IVD原料等行业，得到发酵、生物制药、生物制品、发酵饲料、大学、研究院所、疾病控制中心、体育运动等行业和部门的好评。

As a leader in contract development and manufacturing, Lonza Pharma and Biotech is recognized for our reliable, high-quality services, global capacity, innovative technology platforms, and extensive experience. Our broad capabilities span biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through commercialization, and our expertise covers both drug substance and drug product. We believe that the outcome – for you and your patients – can only come as a results of successful collaboration. Together, we can bring your next medicine to life.
龍沙製藥與生物技術部門, 主要在服務並提供全球合約型訂製開發與製造生產, 讓相關製藥與生物技術公司可以爲病人帶來所需藥物.
從基因到最終藥物產品, 我們所提供的解決方案, 旨在簡化客戶的外包流程, 並滿足客戶所預期的可信結果.
我們的服務經驗十分廣泛, 包括新創性療法的商業化與各種藥物的製造. 我們將持續投資, 來解決當前的問題, 更為了幫客戶戰勝未來的挑戰.
我們將齊心協力, 期待爲您帶來全新的藥物.

Innoforce enables the innovation and global supply of plasmid DNA, mRNA, cell & gene therapeutics, powered by a world-class manufacturing & development hub.
With extensive expertise in process development and manufacturing of Advanced Therapy Medicinal Products (ATMPs), Innoforce can be a trusted partner for your innovative ATMP projects from R&D through commercialization.

源健优科生物科技（上海）有限公司成立于2021年，在中国上海与美国马里兰均设有GMP Site。公司专注于细胞与基因治疗领域的CDMO创新 4*4服务模式，即4大技术平台（质粒、病毒、细胞和mRNA），为4类项目阶段类型（R&D、PD/AD、GMP和IND/BLA filing）的产品提供一站式服务。立足于连续创新优化的技术平台，源健优科可提供临床前研究支持，符合行业标准的工艺设计和开发，保障品质的临床试验和商业化生产，符合IND/CTA/BLA的CMC申报材料的全流程服务。源健优科在具有数十年细胞与基因治疗领域CMC和GMP生产经验的核心团队带领下，建立了完善的质量管理体系，为全球客户提供安全稳定的供应链，灵活地满足客户的各种服务需求。
Forecyte Bio (Shanghai) Co., Ltd was founded in 2021, and our GMP site is located in Shanghai, China and Maryland, USA. We focus on the CDMO innovative 4*4 service model in the field of cell and gene therapy, which provides a one-stop service for 4 types of project stages (R&D, PD/AD, GMP and IND/BLA filing) products by 4 major technology platforms (plasmid, virus, cell and mRNA). Based on the continuous innovative optimized technology platform, we could provide full process services to meet the preclinical research support, process design and development with industry standards, high-quality clinical trials and commercial production, and application materials complied with IND/CTA/BLA CMC. Under the leadership of a core team with decades of CMC and GMP production experience in the field of cell and gene therapy, Forecyte Bio established a complete quality management system to provide a safe and stable supply chain for the global customers and meet their diverse service demands flexibly.

金斯瑞蓬勃生物是金斯瑞的生物医药合同研发生产组织（CDMO），拥有一站式生物药研发生产平台，致力于为抗体药物及基因和细胞治疗药物提供从靶点开发到商业化生产的端到端服务。一站式抗体药开发解决方案涵盖抗体药发现、抗体工程和抗体评价等抗体药服务。在抗体药临床前药学开发方面，金斯瑞蓬勃生物提供细胞系开发、宿主细胞商业化授权、上下游工艺开发、分析方法开发和临床样品生产等一体化CDMO服务加速IND进程。基因细胞治疗整体解决方案涵盖了非注册临床、工艺开发，注册临床和商业化全阶段质粒病毒生产。
金斯瑞蓬勃生物始终以“合作加速创新”为理念，帮助客户缩短生物药进入临床的时间，显著降低客户研发成本，加速医药转化。
GenScript ProBio is the biologics CDMO segment of GenScript, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody drug and gene and cell therapy to accelerate drug development for customers.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery (hybridoma, antibody library, fully human transgenic mice, bispecific antibodies technologies, single b cell screening technology), antibody engineering (antibody humanization, affinity maturation, Fc Engineering) and antibody characterization (analytics and bioassays). In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development, host cell license, process development, analytical development to clinical manufacturing services, providing fed-batch and perfusion process to accelerate IND process and high quality material for clinical trials. GenScript ProBio has successfully delivered multiple CMC and GMP manufacturing projects.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery (hybridoma, antibody library, fully human transgenic mice, bispecific antibodies technologies, single b cell screening technology), antibody engineering (antibody humanization, affinity maturation, Fc Engineering) and antibody characterization (analytics and bioassays). In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development, host cell license, process development, analytical development to clinical manufacturing services, providing fed-batch and perfusion process to accelerate IND process and high quality material for clinical trials. GenScript ProBio has successfully delivered multiple CMC and GMP manufacturing projects.
GenScript ProBio’s total gene and cell therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. Our quality management systems ensure phase appropriate compliance, data integrity and traceability. Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.

苏州博腾生物制药有限公司成立于2018 年12月，立足于苏州工业园区，以上市公司-重庆博腾制药科技股份有限公司（股票代码：300363）为依托，搭建了质粒，病毒载体和细胞治疗产品为一体的CDMO 平台，提供从早期研究、研究者发起的临床、新药临床试验申请（IND）、注册临床试验样品和商业化生产服务，加快药物研究转化进程。
博腾生物聚焦基因与细胞治疗，在博腾股份的成功经验之上，以国际一流的专业人才为核心，秉承“客户第一”的服务宗旨，以“合规、专业、专注、开放协作”为品牌理念，延续母公司强大的IP保护和项目管理机制以及完善的质量管理体系，充分利用核心团队将基因和细胞治疗产品推向临床直至上市的成功经验，为全球客户提供优质和高效的服务，让好药更早惠及大众。
Porton Biologics Ltd. (Portonbio) was established in 2018. Located in Suzhou Industrial Park, and as a subsidiary of Porton Pharma Solutions Ltd, PortonBio provides Gene and Cell Therapy CDMO service for innovators from the early stage, IND filling and even commercial production.
Based on the successful experience of Porton Pharma Solution Ltd, Portonbio will take the international team as the core, adhere to the service concept of “Customer First and Excellence Always”, and take full advantage of high-level technology and equipment to create high-end biological and CDMO platform. Portonbio pursues to become a reliable partner for global pharmaceuticals and biotech companies.

宜明（北京）细胞生物科技有限公司（简称：宜明细胞）成立于2015年10月，是一家致力于基因治疗和细胞治疗技术的开发和应用、能够为基因治疗产业化提供整体解决方案的研发生产型生物技术公司。宜明细胞专家团队为来自美国国立卫生研究院癌症研究所、哈佛大学、霍普金斯大学、马里兰大学、加拿大哥伦比亚大学（UBC）等国际知名院校的教授和研究员，在细胞治疗及基因治疗领域拥有十余年的产业经验。 宜明细胞已建成的济南基地GMP厂房面积达2600㎡，洁净度达到C+A标准，灌装采用绝对A级隔离，并邀请了GMP体系专家全职进行GMP体系建设，按照法规要求建有独立的质粒生产平台、病毒包装平台、细胞培养平台、细胞库平台等，并拥有涵盖生化、微生物、化学的质量检测平台，并实现完全的物理隔离，各平台拥有独立通风系统，全面降低交叉污染的风险。 宜明细胞即将于2021年建成投产的苏州基地GMP新厂房面积达9000㎡，全方位提高GMP级质粒、慢病毒、AAV、腺病毒等产品的产能，全面服务整个行业。 我们邀请了 GMP 体系专家进行 GMP 体系建设，全方位确保为您生产的临床用质粒、临床用病毒等产品符合基因 治疗 IND 申报及新药申报的 GMP 法规要求，降低新药研发的成本、加快新药上市的进度。 宜明细胞定位于生物与健康产业，坚持以成为生物医药的引领者、生命科学的推动者为使命，以推动研发国人用 得起的新型生物药为己任，让包括基因治疗和细胞治疗的药物惠及更多的患者。

查士利华微生物应用技术（上海）有限公司是Charles River的全资子公司，致力于为客户提供尖端的微生物应用技术，以满足制药、家居、个人护理行业多样化需求。我们独一无二的Endosafe®内毒素检测，Celsis®快速微生物检测和Accugenix®微生物鉴定三大品牌业务组合，确保您的生产运营高效，顺畅，降低生产成本，保护公司声誉。
Charles River Microbial Solutions (Shanghai) Co., Ltd. is the subsidiary of Charles River Laboratories Inc. The Microbial Solutions portfolio from Charles River brings you progressive products and services that deliver accurate, relevant, and reliable data to fuel confident decisions on product quality and contamination control. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection, and Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost to manufacture, and protects your reputation.

序祯达生物科技是中国领先的多组学研究和临床服务提供商，致力于基因组学、蛋白组学和其他相关服务。本着以研究为首任，以客户为中心的宗旨，支持药物研发企业进行药物筛选、生物标记物发现和临床试验。 序祯达生物科技提供按照CLIA/CAP标准验证的多样化基因组学和蛋白组学检测，包括基因分型和基因表达qPCR检测，NGS检测和蛋白质生物标志物检测。
其中最具特色的检测包括FoundationOne CDx、用于组织和ctDNA的Illumina TSO500、10x Genomics单细胞解决方案、Olink Target 96/48、Olink Explore 1536/384，及宏基因组、mRNA、smRNA、全基因组和外显子组测序等，并可根据项目需求提供定制化检测

Mission Bio is a life sciences company that accelerates discoveries and cures in oncology by equipping researchers with the tools they need to improve how we measure and predict our resistance and response to cancer therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company’s Tapestri Platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously, from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies around the world to develop treatments and eventually cures for cancer and other rare diseases. To learn more, visit missionbio.com.

恺佧生物（Kactus Biosystems）是一家以研发为驱动的创新型蛋白抗体类国际化生物高科技公司，主要专注于免疫治疗和诊断市场。专属的新型功能重组蛋白和抗体研发生产平台 （Structure Aided Design and Multiplex Screening ,SAMS™）, 服务于全球创新药研发企业客户，提供基于结构设计的功能靶点蛋白，包括膜蛋白及展示其功能结构域和表位的重组蛋白，通过独特的技术及生产体系，高效率、高成功率地解决和突破技术困难，满足了客户的需求。
Kactus Biosystems was founded in Shanghai, China, and strives to be a world-class biotech company to serve global biopharma and diagnostics customers.
● We focus on delivering protein and antibody products and technologies for immune therapy and IVD customers
● We have innovative product development strategies and world-class commercial operations We are solving unmet needs for antigen protein in drug discovery
● Bioactivity Issue: No bioactivity / No activity on cell based assay
● Batch-to-Batch Consistency
● Poor Immunogenicity
● Unavailable, Commercial Antigens: Transmembrane Proteins: GPCR, CD20, etc.
● Cost Effective, Highly Bioactive Enzymes: Capping Enzyme (mRNA transfection & therapeutics)
● Protein / Antibody Engineering Consultation

上海外高桥生物医药园——自贸壹号生命科技产业园（Simbay Park），是星北集团（Simbay Group）旗下专注于医疗企业孵化培育转化的创新服务型产业园。园区依托天然的【自贸+保税】外向型经济区域优势，以合理的空间配置、优美的自然环境及独特的生物医药产业服务，聚焦创新药物、生物技术及创新疗法、高端医疗器械等领域的研发、转化与制造，打造了独特的生物医药“CRO+CDMO+CSO+Capital+CHO（人力资源）+CMO(品牌营销)+EHS（合规管理）”全方位服务平台。园区总规划面积50万平米，一期10万㎡已开放，近100家生物科技创新项目已入驻，现已发展成为新兴国际化生物医药生态园区，为辉大基因、星奕昂、西湖生物、晶泰科技、齐鲁干细胞、维通利华等代表企业创造了高价值及服务。

深研生物是一家生物技术与自动化技术深度结合的研发型企业，专注于细胞治疗和基因治疗领域中的核心技术与核心工艺的研究。
公司使命：利用多学科与生命科学的交叉融合，完成细胞治疗及基因治疗中一系列核心技术与工艺的研发，并推动生物技术研发进入自动化、信息化时代。
公司愿景：提供成本可控、稳定可靠的高度自动化、精准化、个体化的癌症免疫治疗整体解决方案。
公司有三大技术研发平台，包括自动化设备研发平台、生物技术研发平台、生物自动化研发平台。
自动化设备平台核心产品CellSep PRO是国产唯一上市的全封闭自动化细胞处理系统，适用于多种细胞治疗产品的标准化生产，包括CART、TCR-T、NK、骨髓干细胞等。
生物技术平台核心产品EuLV系统是全球首家研发，使用稳定生产细胞株生产慢病毒载体的技术平台，利用EuLV系统生产慢病毒载体的效率是普通慢病毒载体制备方法100-400倍，可在提高病毒载体质量和产量的同时大幅降低制备成本。
Eurekabio is an R&D enterprise which biotechnology combines with automation technology. Eurekabio focuses on the research of core technology and craft from the field of cellular and genetic therapy.
Our goal: The using of life science and multiple subject intercross-amalgamation achieve cellular and genetic therapy including core technology and craft study. Moreover, this intercross-amalgamation promotes biotechnology research into the era of automation and information.
Our vision: supporting an approach of cancer immunotherapy which is controllable cost and stability in the high level of automation, accretion and individuation.
Eurekabio has three main technologic types of research and development including automation equipment, biotechnology, and biomation. CellSep PRO, an automation product, is the only one automated fully enclosed cellular processing system on the Chinese market. CellSep PRO uses in the standardized production of multiple cellular therapies including CART, TCR-T, NK and bone marrow stem cells, etc.
EuLV system, the first biotechnology product in the world, used technology to produce cell strain and lentivirus vector stability. The production of lentivirus vectors in the EuLV system is more 100-400 times efficient than that in standard condition. Furthermore, EuLV system does not only improve the quality and quantity of virus vectors, but also reduce preparation cost significantly.

CPC - Colder Products Company, is the leader in single-use connection technology offering a wide variety of cell and gene therapy connection solutions that ensure ease of use and a robust connection. Single-use technologies (SUT) saves time and labor during set-up and between cycles, by eliminating steps, costs of cleaning, sterilization; and eliminating cross-contaminations between batches. CPC connectors have been tested and validated to comply with accepted industry standards; for mechanical strength; extractables and leachables; bacterial ingress and others. Learn more about the AseptiQuik connectors and our entire portfolio at cpcworldwide.com/cgt to help you to connect with confidence.

云舟生物科技（广州）有限公司创建于2014年3月，是一家集研发、生产及线上销售基因载体的创新型公司，主营业务为基因载体构建产品和相关衍生产品（其中包括病毒包装、蛋白表达纯化等业务 ）及技术服务，以及基于基因治疗临床药物的CDMO业务，涉及全线的工艺开发及生产过程，技术领域涵括分子克隆、细胞生物、蛋白表达纯化及生物信息等。云舟生物自主开发出全球第一款基因载体免费智能设计平台——VectorBuilder（ www.vectorbuilder.cn），即“载体家”，实现了基因载体构建技术的商业化及规模化生产，为广大科研学者提供标准化的基因载体构建服务。云舟生物立足中国，面向全球，将携手全球每一个科研机构、生物制药公司共同致力于基因治疗药物研究，让基因药物治疗不再是奢望。
As a global pioneer in custom DNA vectors and recombinant viruses, VectorBuilder’s revolutionary online-to-offline (O2O) platform provides a powerful one-stop solution to all the vector and virus needs in the life sciences. VectorBuilder has a wide spectrum of offerings, including: Vector design, Custom cloning, Virus packaging, Library construction, BAC recombineering, Mutagenesis, Stable cell line generation and more. Additionally, our state-of-the-art GMP facilities provide GMP-grade vector manufacturing for a wide range of clinical applications. VectorBuilder has delivered hundreds of thousands of custom vectors and recombinant viruses to tens of thousands of researchers in universities and companies across the world, and has received numerous citations in high-impact scientific publications. VectorBuilder’s highly innovative online platform that combines sophisticated yet intuitive vector design capabilities with streamlined online ordering has won multiple awards. Since our initial market launch in 2014, VectorBuilder has grown at an explosive pace to become the world's largest provider of custom vectors and recombinant viruses. Try VectorBuilder (www.vectorbuilder.cn) today and supercharge your research!

广东君厚生物医药有限公司是国内首批提供生产级（GMP级）逆病毒载体和细胞免疫治疗CDMO整体解决方案的公司。本公司拥有建立GMP生产平台的专业核心团队和全套核心技术，主要生产GMP级别的所有基因工程细胞免疫治疗领域的关键制剂，面向国内所有从事CAR-T、TCR-T、细胞治疗和基因编辑等类型的科研院校、医疗机构、研究机构、医药企业，提供细胞免疫治疗CDMO服务的整体解决方案，包括CAR-T细胞免疫产品病毒载体的定制、开发、GMP生产服务等。

法罗斯疫苗（“法罗斯”）株式会社是一家具有开拓精神的生物科技创新公司，利用法罗斯先进的技术平台，尖端灵活的设备设施和专业团队，致力于开发针对人类肿瘤和难以治愈性疾病的创新性生物疗法。 法罗斯基于包括细胞工艺，慢病毒载体系统（CAR-T*/TCR-T*）和蛋白质工程等技术平台，专注开发针对各种肿瘤和难以治愈性疾病的细胞和基因疗法。
法罗斯是利用肿瘤特异性T细胞、嵌合抗原受体T细胞和树突细胞等基因细胞疗法治疗各种癌症和难治疾病如：白血病、淋巴瘤、肝癌、急性心肌梗死（AMI）后的心力衰竭等先进的生物药物商业化先锋。
从长远来看，法罗斯有着清晰的、令人信服且可实现的愿景，即“作为全球细胞和基因治疗与疫苗领域的领导者，打造生物制药行业新典范”。 为了实现这个愿景，法罗斯正沿着正确的轨道前进，并确立了三大战略：一是通过成功募集资金来激发公司未来的增长动力；二是建立，启用了拥有先进仪器设备的全新研发中心和GMP生产平台；并以不懈的努力，与全球法罗斯的合作伙伴一起推动CAR-T疗法的IND和NDA。
Pharos Vaccine is a pioneering BIO venture company, leading the development of innovative biotherapeutics for human cancers and incurable diseases with relevant platform technologies, state-of-the-art and flexible facilities, equipment and human capabilities.
Pharos Vaccine concentrates on the development of cellular and gene therapy for various cancers and incurable diseases on the platform technologies including Cell Processing, Lentiviral Vector System (CAR-T* & TCR-T**) and Protein Engineering. Pharos Vaccine is pioneering the way of commercialization of cutting- edge biomedicines, in which genetic cell therapy represents, for curing various cancers and incurable diseases including leukemia, lymphoma, liver cancer, heart failure post AMI by using tumor-specific T-cells, chimeric antigen receptor T-cells and dendritic cells.
Long-term wise, Pharos Vaccine has a clear, compelling and achievable vision of ‘Lighting the New Paradigm of Vaccine as Global Leader in Vaccine and Therapies’. To realize the vision, Pharos Vaccine is going on the right track with three strategic pillars – one is to trigger developing company’s future growth drivers by successfully gaining needed funds, the other is to relocate to the new office building with own GMP facility and equipment set up, and the last one is to complete filing for IND of CAR-T therapy within the year and afterwards acquire NDA of the therapy in Korea in a relentless manner.

上海曼博生物医药科技有限公司成立于2019年，致力于将全球领先的创新产品和前沿技术带入中国，帮助国内科研工作者在第一时间接触世界范围内的技术革命，并分享研发工具的进步带来的技术红利。
依托于母公司和兄弟公司深厚的资源和超过1400家的国内优质客户群体，生命科学领域的一站式供应链体系，以及高风险生物危险材料进出口平台的优势，曼博生物严格筛选国际创新且经过同行验证过的产品和技术，引入中国市场，开发、孵育和推广。
上海曼博生物医药科技有限公司，集中在为肿瘤/免疫，抗体药物研发，干细胞/细胞治疗/基因治疗领域客户提供尖端小众创新产品，包括提供商业授权灵活的CHO工程细胞株，以支持抗体药物商业化生产；以及提供从Research grade到cGMP等级的非动物源培养基质，基因编辑工具，病毒载体，转染试剂，病毒转导试剂等产品和定制服务，支持ATMP（Advance Therapy Medicinal Products）药物研发从R&D到Clinical trial以及后期商业化的无缝转化。

Sartorius Stedim Biotech is a leading international provider of integrated solutions for the biopharmaceutical industry. With our extensive portfolio of products, technologies and services, we cover wide areas of the biopharmaceutical process chain, ranging from fermentation, cell cultivation, filtration and purification to media storage and transportation. In process filtration, fermentation and fluid management, our company holds leading positions in the markets it serves across the globe. Our single-use products that have meanwhile become established in nearly all process steps are playing an increasingly important role in the manufacture of biopharmaceuticals. As a result, we help our customers produce biological medications and vaccines safely and efficiently.

Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development. A leader in centrifugation and flow cytometry, Beckman Coulter has long been an innovator in life sciences instruments and solutions used at the forefront of important areas of investigation, including genomics, proteomics and cellular research.

同腾睿杰（上海）生物科技有限公司是一家专业的生命科学仪器销售的公司，是上海同腾生物科技有限公司的兄弟公司，主要服务于生命科学、生物制药和免疫肿瘤领域，客户主要为高等院校、药物研究所、制药企业等。自公司成立以来，凭借先进的软硬件基础及丰富的行业实践经验，为相关领域的研究人员提供国际上最前沿的实验室成套设备，满足各类科学研究的需求。

MCE 致力于为全球客户提供新颖齐全的高品质小分子活性化合物。30000 多种特异性抑制剂、激动剂作用于表观遗传学、PI3K/Akt/mTOR、凋亡、MAPK、Wnt 等 20 个信号通路的 500+ 个靶点蛋白，覆盖癌症、神经科学、免疫学等热门疾病研究领域。MCE 的 100 多种活性化合物库，包含 15000 多种具有生物活性的小分子化合物，可用于 高通量筛选 (HTS) 和 高内涵筛选 (HCS)，是进行新药筛选和新适应症发现等研究的专业工具。MCE 拥有众多全球独家化合物，并有专业团队追踪新的制药及生命科学研究进展，能够为您提供新近研究的活性化合物，以满足您的科研需求。

关于安捷伦
安捷伦科技有限公司（纽约证交所：A）是生命科学、诊断和应用化学市场领域的全球领导者，致力于为提升人类生活品质提供敏锐洞察和创新经验。安捷伦的仪器、软件、服务、解决方案和专家能够为客户最具挑战性的难题提供更可靠的答案。2020财年，安捷伦营业收入为53.4亿美元，全球员工数约为16,400人。

Marken is a wholly owned subsidiary of the UPS Healthcare division. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 56 locations worldwide, while maintaining the leading position for Direct to Patient and Home Health care services, biological sample shipments and biological kit production. Marken’s dedicated 1300 staff members manage 85,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.

上海（南翔）精准医学产业园是创新型政产学研产业化平台。产业园围绕精准诊断、精准治疗、精准康复、精准预防四大核心领域，以专业化、市场化和国际化的运营机制汇聚全球精准医学创新创业资源，构建“精准医学产业化研究院”、“精准医学产业转化平台”、“精准医学临床应用平台”、“上海精准医学产业投资基金”四位一体的创新生态系统，打造全球精准医学产业化新高地，成为精准医学创新成果转化地、创新主体集聚地和创新要素集散地，代表上海和中国参与全球在精准医学领域的竞争。

BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product. The company is the industry’s third largest, with major operations in China and the US—featuring more than 2,000 employees and 10 global sites.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The company has research sites, as well as GMP manufacturing facilities in both China and the US. The one-stop-shop operation helps biopharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes.
保诺-桑迪亚，安宏资本旗下投资企业之一。保诺-桑迪亚是一家领先的合同研究、工艺开发和生产公司（CRDMO公司），专业为生物制药客户提供全面整合服务，支持药物的发现、开发和生产，包括原料药和制剂。作为世界第三大CRDMO公司，保诺-桑迪亚在全球10大分支机构拥有超过2,000名团队成员，在中国和美国开展其主要业务。
保诺-桑迪亚在大小分子发现、开发和放大方面有深厚而丰富的专业知识，支持IND申报，拥有独特的专利技术平台（例如难溶化合物生物有效性增强平台）。公司在中国和美国均设有研发中心和生产基地。保诺-桑迪亚“一站式”运营模式，有效帮助生物制药客户加快发现和降低开发风险，从而创造更高的价值。

Johnson Matthey Pharmaceutical Services (Yantai) Co., Ltd is a 100% holding company of Johnson Matthey Group, and is a part of our Innovator business unit in Health Sector. Along with the JM global network in Pharma Services, Chiral Technology and API business, JM Yantai site has an established a strong team in R&D and management based on easily accessible raw material and sufficient talent pool which allow us to supply tailored technology, process R&D services, advanced intermediate and API production for high-end innovator pharmaceutical clients.

明捷医药是一家提供一站式的药物质量研究及生产放行解决方案的第三方技术服务公司。在南京药谷、上海张江药谷、上海国际医学园区分别设有独立的质量控制实验室，面积共5000多平方米。明捷医药参照cGMP和CNAS质量体系建立了支持药品注册申报及生产放行的一体化药物质量控制实验室，为客户提供符合全球药政法规的药物质量研究、基因毒杂质研究、包材相容性研究、元素杂质研究、生物药工艺残留物研究、原料药备案、注射剂一致性评价等多项技术服务。
公司秉承“专业、创新、合作、责任”的理念，不断加强能力建设、质量体系建设及人才队伍建设，以专业的技术团队和合规的质量体系为客户提供高效率、高质量、合规的技术服务，一起为医药事业和人类健康而努力。
Milestone Pharma is a third-party technical service company that provides one-stop solutions for drug quality research and product release testing services. Milestone Pharma has three independent quality control laboratories in Nanjing Medicine Valley, Shanghai Zhangjiang Medicine Valley and Shanghai International Medical Zone , covering a layout area of more than 5,000 square meters. Milestone Pharma has established an integrated drug quality control procedures to support drug registration application and drug product release in compliance with cGMP and CNAS quality systems. We provide technical services including drug quality study, genotoxic impurity study, packaging material compatibility study (extractables and leachables), elemental impurity study, biological drug process residue study, DMF filing, generic drug consistency evaluation in compliance with global drug regulations.
Adhering to the concept of "specialty, innovation, cooperation and responsibility", we continuously strengthen on the improvement of capability, quality system and talent teams. We aim to provide customers with efficient, high-quality and well-compliant technical services with professional technical teams and GMP quality system.The quality of human health and pharmaceutical industry, we care and endeavor!

HitGen is a rapidly growing biotech company with headquarters based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for hundreds of billions of novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.